NEOGENOMICS INC (NEO) — SEC Financial Statements & Analysis

NEOGENOMICS INC (NEO) is a services-testing laboratories company, incorporated in NV. NEOGENOMICS INC trades on Nasdaq as: NEO. NEOGENOMICS INC (NEO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-28. Based on that filing, NEOGENOMICS INC carries a market cap of $958.41M, a P/E ratio of -9.66x, a P/B ratio of 1.16x, a P/S ratio of 1.28x, an enterprise value of $1.15B, and an EV/EBITDA multiple of -16.30x. On profitability, it posts a gross margin of 43.15%, an operating margin of -14.25%, a net margin of -13.30%, a Return on Equity (ROE) of -11.56%, a Return on Assets (ROA) of -6.73%, and a Return on Invested Capital (ROIC) of -9.66%. Per share, it reports EPS of $-0.77, diluted EPS of $-0.77, free cash flow per share of $-0.04, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.95% year-over-year, net income growth of 27.87% year-over-year, and EPS growth of 26.09% year-over-year. On the balance sheet, it maintains a current ratio of 4.42x, a quick ratio of 3.79x, working capital of $289.09M, a debt-to-equity ratio of 0.62x, a debt ratio of 0.38, an interest coverage ratio of -38.89x, free cash flow of $-5.09M (TTM), and net debt of $196.10M. Figures sourced from SEC EDGAR.

Market Cap

$958.41M

P/E TTM

-9.66x

EPS TTM

$-0.77

P/B TTM

1.16x

ROE TTM

-11.56%

ROA TTM

-6.73%

Debt To Equity

0.62x

Free Cash Flow TTM

$-5.09M

Net Revenue TTM Growth 1Y

10.95%

Data as of 2026-03-31 · Source: SEC EDGAR